Massi D - Search Results

1

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

O'Donnell JS, Massi D, Teng MWL, Mandala M. O'Donnell JS, et al. Among authors: massi d. Semin Cancer Biol. 2018 Feb;48:91-103. doi: 10.1016/j.semcancer.2017.04.015. Epub 2017 May 2. Semin Cancer Biol. 2018. PMID: 28467889 Review.

2

Squamoproliferative skin lesion during braf inhibitors:one size does not fit all.

Mandalà M, Gianatti A, Massi D. Mandalà M, et al. Among authors: massi d. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):389-91. doi: 10.1111/jdv.12196. Epub 2013 Jun 14. J Eur Acad Dermatol Venereol. 2014. PMID: 23763655 No abstract available.

3

Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action.

Mandalà M, Massi D, De Giorgi V. Mandalà M, et al. Among authors: massi d. Crit Rev Oncol Hematol. 2013 Nov;88(2):318-37. doi: 10.1016/j.critrevonc.2013.06.002. Epub 2013 Jul 3. Crit Rev Oncol Hematol. 2013. PMID: 23830782 Review.

4

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.

Merelli B, Massi D, Cattaneo L, Mandalà M. Merelli B, et al. Among authors: massi d. Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65. doi: 10.1016/j.critrevonc.2013.08.002. Epub 2013 Aug 28. Crit Rev Oncol Hematol. 2014. PMID: 24029602 Review.

5

Tissue prognostic biomarkers in primary cutaneous melanoma.

Mandalà M, Massi D. Mandalà M, et al. Among authors: massi d. Virchows Arch. 2014 Mar;464(3):265-81. doi: 10.1007/s00428-013-1526-x. Epub 2014 Feb 1. Virchows Arch. 2014. PMID: 24487785 Review.

6

Nras in melanoma: targeting the undruggable target.

Mandalà M, Merelli B, Massi D. Mandalà M, et al. Among authors: massi d. Crit Rev Oncol Hematol. 2014 Nov;92(2):107-22. doi: 10.1016/j.critrevonc.2014.05.005. Epub 2014 Jun 12. Crit Rev Oncol Hematol. 2014. PMID: 24985059 Review.

7

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.

Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, Mandalà M. Massi D, et al. Ann Oncol. 2014 Dec;25(12):2433-2442. doi: 10.1093/annonc/mdu452. Epub 2014 Sep 15. Ann Oncol. 2014. PMID: 25223485 Free article.

8

Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma.

Massi D, Simi L, Sensi E, Baroni G, Xue G, Scatena C, Caldarella A, Pinzani P, Fontanini G, Carobbio A, Urso C, Mandalà M. Massi D, et al. Mod Pathol. 2015 Apr;28(4):487-97. doi: 10.1038/modpathol.2014.137. Epub 2014 Oct 24. Mod Pathol. 2015. PMID: 25341653 Free article.

9

The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.

Massi D, Brusa D, Merelli B, Falcone C, Xue G, Carobbio A, Nassini R, Baroni G, Tamborini E, Cattaneo L, Audrito V, Deaglio S, Mandalà M. Massi D, et al. Ann Oncol. 2015 Sep;26(9):1980-1987. doi: 10.1093/annonc/mdv255. Epub 2015 Jun 2. Ann Oncol. 2015. PMID: 26037795 Free article.

10

Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.

Xue G, Zippelius A, Wicki A, Mandalà M, Tang F, Massi D, Hemmings BA. Xue G, et al. Among authors: massi d. J Natl Cancer Inst. 2015 Jun 11;107(7):djv171. doi: 10.1093/jnci/djv171. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 26071042 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

445 results

Search Page